Αρχική World News Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to Elective...

Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to Elective Neck Dissection in Early Oral Cancer

A study performed in 16 institutions in Japan shows that sentinel lymph node biopsy (SLNB)-navigated neck dissection is not inferior and it is less invasive than elective neck dissection in patients with early stage oral cavity squamous cell carcinoma (OCSCC). The study results may promote a widespread use of SLNB-navigated and replace elective neck dissection without a survival disadvantage and reducing also postoperative neck disability in this population. The findings are published on 20 April 2021 in the Journal of Clinical Oncology.

Potential strategies for managing patients with early OCSCC include observation, elective neck dissection, and SLNB. A large-scale randomised controlled trial reported previously the superiority of elective neck dissection over observation. However, avoiding unnecessary neck dissection prevents risks and complications, thus reducing surgical intervention and prolonged hospitalisation. The authors wrote in the background that there is insufficient evidence supporting a single strategy.

SLNB has been established as the method for staging patients with clinically N0 breast cancer and cutaneous melanoma and provides useful information of the nodal status. Appropriate neck dissection might be achieved if SLNB is used for treating OCSCC. Since reports of SLNB for OCSCC are limited and detection methods vary, a prospective multi-institutional study with numerous cases constituting unified methodologies is essential for verifying the validity of SLNB.

In this randomised, multicentre, noninferiority, phase III study, patients of age ≥18 years with histologically confirmed, previously untreated early OCSCC were randomly assigned to undergo elective neck dissection (n=137) or SLNB-navigated neck dissection (n=134).

The primary endpoint was the 3-year overall survival (OS) rate, with a 12% noninferiority margin; secondary endpoints included postoperative neck functionality and complications and 3-year disease-free survival (DFS). The SLNs underwent intraoperative multislice frozen section analyses for the diagnosis. Patients with positive SLN underwent either one-stage or second-look neck dissection.

The study team reported that pathologic metastasis-positive nodes were observed in 24.8% (34 of 137) and 33.6% (46 of 134) of patients in the elective neck dissection and SLNB groups, respectively (p = 0.190).

The 3-year OS in the SLNB group (87.9%) was noninferior to that in the elective neck dissection group (86.6%); p for noninferiority < 0.001.

The 3-year DFS was 78.7% and 81.3% in the SLNB and elective neck dissection groups, respectively (p for noninferiority < 0.001).

The scores of neck functionality in the SLNB group were significantly better than those in the elective neck dissection group.

The authors also commented that performing SLNB appropriately requires the expertise of a skilled head and neck surgeon, along with the collaborative efforts of a radiologist and a pathologist for pre-, post-, and intraoperative diagnoses.


Hasegawa Y, Tsukahara K, Yoshimoto S, et al. Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial. JCO; Published online 20 April 2021. DOI: 10.1200/JCO.20.03637 



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...